Literature DB >> 8515103

Comparative prophylactic efficacy of cefazolin and vancomycin in a guinea pig model of Staphylococcus aureus wound infection.

D S Kernodle1, A B Kaiser.   

Abstract

The increasing prevalence of methicillin-resistant Staphylococcus aureus as a wound pathogen in some institutions has prompted the use of vancomycin for surgical prophylaxis, although clinical data comparing vancomycin and cephalosporins are not available. A guinea pig model was used to compare the efficacy of vancomycin and cefazolin in preventing intermuscular abscess formation by 7 S. aureus strains. Both antibiotics were administered to achieve peak serum levels at the time of bacterial inoculation, and each remained > 1 micrograms/mL for a comparable duration. Vancomycin provided equivalent protection from infection by 1 methicillin-susceptible strain and significantly better protection against 4 methicillin-susceptible and both methicillin-resistant S. aureus strains. For most strains, the bacterial inoculum with a 50% probability of causing an abscess was 2 to 4 log10-fold higher with vancomycin than cefazolin prophylaxis. Prophylaxis with vancomycin is superior to cefazolin in preventing intermuscular infection by methicillin-susceptible and -resistant S. aureus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8515103     DOI: 10.1093/infdis/168.1.152

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Development of an experimental model of infected skin ulcer.

Authors:  Masahiro Tachi; Shinichi Hirabayashi; Yoshiyuki Yonehara; Yasutoshi Suzuki; Philip Bowler
Journal:  Int Wound J       Date:  2004-04       Impact factor: 3.315

2.  Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

Authors:  Keso Skhirtladze; Doris Hutschala; Tatjana Fleck; Florian Thalhammer; Marek Ehrlich; Thomas Vukovich; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Synergism between poly-(1-6)-beta-D-glucopyranosyl-(1-3)-beta-D-glucopyranose glucan and cefazolin in prophylaxis of staphylococcal wound infection in a guinea pig model.

Authors:  A B Kaiser; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection.

Authors:  D S Kernodle; H Gates; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery.

Authors:  Loren G Miller; James A McKinnell; Michael E Vollmer; Brad Spellberg
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

6.  Efficacy and pharmacokinetics of site-specific cefazolin delivery using biodegradable implants in the prevention of post-operative wound infections.

Authors:  S Allababidi; J C Shah
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

7.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  Vancomycin for the treatment of methicillin-resistant staphylococcal and enterococcal infections in 15 horses.

Authors:  James A Orsini; Corinna Snooks-Parsons; Lynne Stine; Marie Haddock; Charles F Ramberg; Charles E Benson; David M Nunamaker
Journal:  Can J Vet Res       Date:  2005-10       Impact factor: 1.310

Review 9.  The guinea pig as a model of infectious diseases.

Authors:  Danielle J Padilla-Carlin; David N McMurray; Anthony J Hickey
Journal:  Comp Med       Date:  2008-08       Impact factor: 0.982

10.  Evaluation of antibiotic-loaded calcium phosphate bone cement in an cranium-infected experimental model.

Authors:  Yoshiaki Sakamoto; Hiroko Ochiai; Ikuko Ohsugi; Yoshikazu Inoue; Yoko Yoshimura; Kazuo Kishi
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-03-27       Impact factor: 1.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.